Published in Eur J Epidemiol on June 17, 2009
The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol (2011) 3.26
The Generation R Study: design and cohort update 2010. Eur J Epidemiol (2010) 1.85
Cardiovascular and metabolic influences of fetal smoke exposure. Eur J Epidemiol (2011) 1.02
Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol (2010) 1.00
The Shanghai Changfeng Study: a community-based prospective cohort study of chronic diseases among middle-aged and elderly: objectives and design. Eur J Epidemiol (2010) 0.96
Association between microalbuminuria and subclinical atherosclerosis evaluated by carotid artery intima-media in elderly patients with normal renal function. BMC Nephrol (2012) 0.90
Early influences on cardiovascular and renal development. Eur J Epidemiol (2010) 0.90
The dynamics of cardiovascular epidemiology. Eur J Epidemiol (2009) 0.81
Hypovolaemia was associated with clustering of major cardiovascular risk factors in general population. BMC Cardiovasc Disord (2014) 0.75
Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12
Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 24.72
Permutation tests for joinpoint regression with applications to cancer rates. Stat Med (2000) 24.62
Worldwide prevalence of hypertension: a systematic review. J Hypertens (2004) 6.25
Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J (2001) 5.69
Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med (1998) 5.63
Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension (2003) 5.63
Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q (1988) 5.50
Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA (1993) 4.75
Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J (2000) 2.90
Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA (1995) 2.87
The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J (1997) 2.72
INTERSALT study findings. Public health and medical care implications. Hypertension (1989) 2.69
Sodium intake and hypertension. Prog Cardiovasc Dis (2006) 2.39
Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart (2002) 2.34
Epidemiological studies related to coronary heart disease: characteristics of men aged 40-59 in seven countries. Acta Med Scand Suppl (1966) 2.20
Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N Engl J Med (1994) 2.09
Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 1970 and 2000. Eur Heart J (2005) 1.91
Status and management of blood lipids in Greek adults and their relation to socio-demographic, lifestyle and dietary factors: the ATTICA Study. Blood lipids distribution in Greece. Atherosclerosis (2004) 1.64
The high-fat Greek diet: a recipe for all? Eur J Clin Nutr (2002) 1.46
Prevalence, awareness, treatment and control of hypertension in a general population sample of 26,913 adults in the Greek EPIC study. Int J Epidemiol (2004) 1.42
Epidemiology of overweight and obesity in a Greek adult population: the ATTICA Study. Obes Res (2004) 1.31
Risk factors for ischaemic heart disease in a Greek population. A cross-sectional study of men and women living in the village of Spili in Crete. Eur Heart J (1992) 1.18
Food consumption patterns in the 1960s in seven countries. Am J Clin Nutr (1989) 1.15
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
First national epidemiological survey on the prevalence of obesity and abdominal fat distribution in Greek adults. Ann Nutr Metab (2006) 1.02
Socio-economic status in relation to risk factors associated with cardiovascular disease, in healthy individuals from the ATTICA study. Eur J Cardiovasc Prev Rehabil (2005) 0.98
The treatment of coronary heart disease: an update. Part 2: Mortality trends and main causes of death in the Greek population. Curr Med Res Opin (2001) 0.95
Coronary heart disease risk factors in a random sample of Athenian adults. The Athens Study. Am J Epidemiol (1987) 0.93
Nutrition and health. Eur Heart J (1992) 0.92
Mortality among urban bus drivers. Int J Epidemiol (1991) 0.91
Physical activity, high density lipoprotein cholesterol and other lipids levels, in men and women from the ATTICA study. Lipids Health Dis (2003) 0.91
Heart disease, cancer, and stroke mortality trends and their interrelations. An international perspective. Circulation (1994) 0.88
CRETE: A STUDY IN THE METABOLIC EPIDEMIOLOGY OF CORONARY HEART DISEASE. Am J Cardiol (1965) 0.87
Prevention in childhood and youth of adult cardiovascular diseases: time for action. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser (1990) 0.87
Association between trans fatty acid intake and cardiovascular risk factors in Europe: the TRANSFAIR study. Eur J Clin Nutr (2000) 0.86
Evidence for an increase in the prevalence of known diabetes in a sample of an urban population in Greece. Diabet Med (1993) 0.83
The secular trend of body weight of Greek schoolchildren in the 20th century. Med Sci Monit (2006) 0.79
Twenty-five-year prediction of stroke deaths in the seven countries study: the role of blood pressure and its changes. Stroke (1996) 0.78
Changes of nutrition patterns and health indicators at the population level in Greece. Am J Clin Nutr (1989) 0.75
Coronary heart disease in seven countries. XV. Prognosis of coronary heart disease found at entry. Circulation (1970) 0.75
A review of drug-induced hyponatremia. Am J Kidney Dis (2008) 2.97
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation (2004) 1.91
Therapeutic approach in patients with dysnatraemias. Nephrol Dial Transplant (2006) 1.90
Association of Helicobacter pylori infection with cardiovascular disease--is it just a myth? Eur J Intern Med (2010) 1.67
Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin (2010) 1.56
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
Benign migratory glossitis or geographic tongue: an enigmatic oral lesion. Am J Med (2002) 1.49
Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost (2003) 1.45
Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose. Metab Syndr Relat Disord (2012) 1.44
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem (2005) 1.40
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin (2011) 1.39
Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
A review of drug-induced hypocalcemia. J Bone Miner Metab (2009) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
Apolipoprotein E and renal disease. Am J Kidney Dis (2004) 1.20
Novel roles of vitamin D in disease: what is new in 2011? Eur J Intern Med (2011) 1.14
Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol (2006) 1.12
LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis (2006) 1.12
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
Prediabetes: to treat or not to treat? Eur J Pharmacol (2011) 1.11
Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J (2011) 1.06
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol (2007) 1.05
Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy. JOP (2003) 1.04
Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism (2006) 1.02
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des (2010) 1.02
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther (2007) 1.01
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol (2011) 1.00
Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res (2002) 1.00
Early vascular benefits of statin therapy. Curr Med Res Opin (2003) 0.99
Severe hypocholesterolemia with reduced serum lipoprotein(a) in a patient with visceral leishmaniasis. Ann Clin Lab Sci (2002) 0.98
Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin (2004) 0.97
Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol (2007) 0.97
Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail (2002) 0.97
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci (2011) 0.96
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin (2007) 0.96
Influence of smoking on predictors of vascular disease. Angiology (2003) 0.96
Clinical and laboratory characteristics of hypernatraemia in an internal medicine clinic. Nephrol Dial Transplant (2007) 0.96
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology (2011) 0.94
Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids (2007) 0.94
Benchmarking is associated with improved quality of care in type 2 diabetes: the OPTIMISE randomized, controlled trial. Diabetes Care (2013) 0.93
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol (2002) 0.93
Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology (2005) 0.93
Statin pleiotropy against renal injury. J Cardiometab Syndr (2009) 0.92
Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum (2008) 0.92
Pharmacologically-induced metabolic acidosis: a review. Drug Saf (2010) 0.92
Native valve endocarditis due to Micrococcus luteus: a case report and review of the literature. J Med Case Rep (2011) 0.91
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther (2006) 0.91
Hyponatremia in patients with infectious diseases. J Infect (2011) 0.91
Disturbances of phosphate metabolism: another feature of metabolic syndrome. Am J Kidney Dis (2005) 0.91
The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids (2006) 0.91
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol (2011) 0.90
The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. Arch Med Sci (2012) 0.89
Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. Eur J Prev Cardiol (2012) 0.89
Persistent erythema multiforme in a patient with extrahepatic cholangiocarcinoma. Oncology (2008) 0.89
The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol (2008) 0.89
Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin (2003) 0.89
Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects. Arch Med Res (2009) 0.89
Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental? Atherosclerosis (2009) 0.89
Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin (2004) 0.88
Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: an ultrasonographic study. Atherosclerosis (2008) 0.88
Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res (2003) 0.87
The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther (2003) 0.87
Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism (2005) 0.87
Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. J Cardiovasc Pharmacol Ther (2006) 0.87
Lipoprotein glomerulopathy. Curr Opin Lipidol (2011) 0.86
Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids (2005) 0.86
Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol (2010) 0.86
Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus. Cardiovasc Diabetol (2011) 0.86
Increased serum ferritin concentrations and liver enzyme activities in patients with metabolic syndrome. Metab Syndr Relat Disord (2006) 0.84
How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Curr Med Res Opin (2014) 0.84
Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant (2007) 0.84
Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels. J Cardiovasc Pharmacol Ther (2013) 0.84
Alarming atrioventricular block and mitral valve prolapse in the Kearns-Sayre syndrome. Int J Cardiol (2002) 0.84
No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. Drug Metabol Personal Ther (2015) 0.84
Endocrine disorders: causes of hyponatremia not to neglect. Ann Med (2010) 0.84
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens (2002) 0.83
Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. J Cardiovasc Pharmacol Ther (2012) 0.83
LDL-cholesterol calculation formulas in patients with or without the metabolic syndrome. Int J Cardiol (2006) 0.83
Hypokalemia due to Fanconi syndrome in a patient with obstructive jaundice. Nephron (2002) 0.83
The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Expert Opin Ther Targets (2007) 0.83
Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol (2011) 0.83
Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol (2011) 0.83
Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece. Angiology (2011) 0.83
Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. Lipids (2011) 0.83